178 related articles for article (PubMed ID: 38063193)
1. An LGR4 agonist activates the GSK‑3β pathway to inhibit RANK‑RANKL signaling during osteoclastogenesis in bone marrow‑derived macrophages.
Jang Y; Lee H; Cho Y; Choi E; Jo S; Sohn HM; Kim BC; Ko YJ; Lim W
Int J Mol Med; 2024 Jan; 53(1):. PubMed ID: 38063193
[TBL] [Abstract][Full Text] [Related]
2. LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption.
Luo J; Yang Z; Ma Y; Yue Z; Lin H; Qu G; Huang J; Dai W; Li C; Zheng C; Xu L; Chen H; Wang J; Li D; Siwko S; Penninger JM; Ning G; Xiao J; Liu M
Nat Med; 2016 May; 22(5):539-46. PubMed ID: 27064449
[TBL] [Abstract][Full Text] [Related]
3. Microtubule actin crosslinking factor 1 (MACF1) knockdown inhibits RANKL-induced osteoclastogenesis via Akt/GSK3β/NFATc1 signalling pathway.
Lin X; Xiao Y; Chen Z; Ma J; Qiu W; Zhang K; Xu F; Dang K; Qian A
Mol Cell Endocrinol; 2019 Aug; 494():110494. PubMed ID: 31260729
[TBL] [Abstract][Full Text] [Related]
4. PDK1 is important lipid kinase for RANKL-induced osteoclast formation and function via the regulation of the Akt-GSK3β-NFATc1 signaling cascade.
Xiao D; Zhou Q; Gao Y; Cao B; Zhang Q; Zeng G; Zong S
J Cell Biochem; 2020 Nov; 121(11):4542-4557. PubMed ID: 32048762
[TBL] [Abstract][Full Text] [Related]
5. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
6. Sappanone A inhibits RANKL-induced osteoclastogenesis in BMMs and prevents inflammation-mediated bone loss.
Choo YY; Tran PT; Min BS; Kim O; Nguyen HD; Kwon SH; Lee JH
Int Immunopharmacol; 2017 Nov; 52():230-237. PubMed ID: 28946117
[TBL] [Abstract][Full Text] [Related]
7. Effects of moderate intensity static magnetic fields on osteoclastic differentiation in mouse bone marrow cells.
Kim EC; Park J; Noh G; Park SJ; Noh K; Kwon IK; Ahn SJ
Bioelectromagnetics; 2018 Jul; 39(5):394-404. PubMed ID: 29709064
[TBL] [Abstract][Full Text] [Related]
8. Purple tea water extract blocks RANKL-induced osteoclastogenesis through modulation of Akt/GSK3β and Blimp1-Irf8 pathways.
Zhang Y; Wang J; Jing C; Zhou MX; Jin W; Yan X; Hou H; Shi K; Sun WC; Sun L
Food Funct; 2022 Aug; 13(17):8850-8859. PubMed ID: 35920249
[TBL] [Abstract][Full Text] [Related]
9. A novel modified RANKL variant can prevent osteoporosis by acting as a vaccine and an inhibitor.
Ko YJ; Sohn HM; Jang Y; Park M; Kim B; Kim B; Park JI; Hyun H; Jeong B; Hong C; Lim W
Clin Transl Med; 2021 Mar; 11(3):e368. PubMed ID: 33784004
[TBL] [Abstract][Full Text] [Related]
10. Garcinol suppresses RANKL-induced osteoclastogenesis and its underlying mechanism.
Jia Y; Jiang J; Lu X; Zhang T; Zhao K; Han W; Yang W; Qian Y
J Cell Physiol; 2019 May; 234(5):7498-7509. PubMed ID: 30471112
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of RANKL-Induced Osteoclastogenesis by Novel Mutant RANKL.
Jang Y; Sohn HM; Ko YJ; Hyun H; Lim W
Int J Mol Sci; 2021 Jan; 22(1):. PubMed ID: 33406741
[TBL] [Abstract][Full Text] [Related]
12. Gypenoside inhibits RANKL-induced osteoclastogenesis by regulating NF-κB, AKT, and MAPK signaling pathways.
Han J; Gao W; Su D; Liu Y
J Cell Biochem; 2018 Sep; 119(9):7310-7318. PubMed ID: 29797602
[TBL] [Abstract][Full Text] [Related]
13. Glaucocalyxin A suppresses osteoclastogenesis induced by RANKL and osteoporosis induced by ovariectomy by inhibiting the NF-κB and Akt pathways.
Zhu M; Shan J; Xu H; Xia G; Xu Q; Quan K; Liu X; Dai M
J Ethnopharmacol; 2021 Aug; 276():114176. PubMed ID: 33933570
[TBL] [Abstract][Full Text] [Related]
14. The fungal metabolite (+)-terrein abrogates osteoclast differentiation via suppression of the RANKL signaling pathway through NFATc1.
Nakagawa S; Omori K; Nakayama M; Mandai H; Yamamoto S; Kobayashi H; Sako H; Sakaida K; Yoshimura H; Ishii S; Ibaragi S; Hirai K; Yamashiro K; Yamamoto T; Suga S; Takashiba S
Int Immunopharmacol; 2020 Jun; 83():106429. PubMed ID: 32222639
[TBL] [Abstract][Full Text] [Related]
15. Desoxyrhapontigenin inhibits RANKL‑induced osteoclast formation and prevents inflammation‑mediated bone loss.
Tran PT; Park DH; Kim O; Kwon SH; Min BS; Lee JH
Int J Mol Med; 2018 Jul; 42(1):569-578. PubMed ID: 29693149
[TBL] [Abstract][Full Text] [Related]
16. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.
Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC
Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379
[TBL] [Abstract][Full Text] [Related]
17. Anethole inhibits RANKL-induced osteoclastogenesis by downregulating ERK/AKT signaling and prevents ovariectomy-induced bone loss in vivo.
Qu H; Zhang Y; He R; Lin N; Wang C
Int Immunopharmacol; 2021 Nov; 100():108113. PubMed ID: 34530203
[TBL] [Abstract][Full Text] [Related]
18. Monotropein Protects against Inflammatory Bone Loss and Suppresses Osteoclast Formation and Bone Resorption by Inhibiting NFATc1 via NF-κB and Akt/GSK-3β Pathway.
Zhang Q; Hu S; He Y; Song Z; Shen Y; Zhao Z; Zhang Q; Qin L; Zhang Q
Nutrients; 2022 Sep; 14(19):. PubMed ID: 36235631
[TBL] [Abstract][Full Text] [Related]
19. Ethyl Acetate Fraction of Aqueous Extract of Lentinula edodes Inhibits Osteoclastogenesis by Suppressing NFATc1 Expression.
Lee H; Lee K; Lee S; Lee J; Jeong WT; Lim HB; Hyun TK; Yi SJ; Kim K
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32079267
[TBL] [Abstract][Full Text] [Related]
20. AKT/GSK3β/NFATc1 and ROS signal axes are involved in AZD1390-mediated inhibitory effects on osteoclast and OVX-induced osteoporosis.
Yang S; Song D; Wang Z; Su Y; Chen J; Xian Y; Huang J; Li J; Xu J; Zhao J; Liu Q
Int Immunopharmacol; 2022 Dec; 113(Pt A):109370. PubMed ID: 36327872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
